Solventum Corporation (SOLV) encountered significant activities during this period. Following the sale of its Purification & Filtration business to Thermo Fisher Scientific for a staggering $4.1B, stock ownership heightened as US Bancorp DE and Bank of New York Mellon Corp lifted their positions, alongside Savant Capital LLC's acquisition. Institutional shareholders also play a substantial role, holding approximately 63-64% of the company, which motivated investment decisions. Despite a falling stock and lower Q4 adjusted earnings, it still managed to beat estimates while revealing positive Q4 2024 financial results. This led analysts from Morgan Stanley and Bank of America to predict a rise in stock price. Entering 2025, the firm outpaced the Healthcare Information Services market, anticipated further business simplifications and committed to a 100% renewable electricity goal by 2030. They are currently in the early stages of a multi year turnaround effort and their healthcare AI technology and radiology tech grabbed their fifth KLAS victory. Yet layoffs were announced and despite a forecast of annual profit above estimates, SOLV still stumbled and was deemed a sell.
Solventum Corporation SOLV News Analytics from Mon, 01 Apr 2024 07:00:00 GMT to Sat, 08 Mar 2025 06:27:58 GMT -
Rating 4
- Innovation 5
- Information 8
- Rumor -3
